NBRV vs. AADI, GANX, RMTI, BOLT, IMRX, CKPT, CARA, LEXX, UNCY, and EQ
Should you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Aadi Bioscience (AADI), Gain Therapeutics (GANX), Rockwell Medical (RMTI), Bolt Biotherapeutics (BOLT), Immuneering (IMRX), Checkpoint Therapeutics (CKPT), Cara Therapeutics (CARA), Lexaria Bioscience (LEXX), Unicycive Therapeutics (UNCY), and Equillium (EQ). These companies are all part of the "pharmaceutical preparations" industry.
Nabriva Therapeutics (NASDAQ:NBRV) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings.
In the previous week, Aadi Bioscience had 5 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 6 mentions for Aadi Bioscience and 1 mentions for Nabriva Therapeutics. Aadi Bioscience's average media sentiment score of 0.10 beat Nabriva Therapeutics' score of 0.00 indicating that Aadi Bioscience is being referred to more favorably in the news media.
Nabriva Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.
Nabriva Therapeutics received 382 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 58.40% of users gave Nabriva Therapeutics an outperform vote while only 50.00% of users gave Aadi Bioscience an outperform vote.
Nabriva Therapeutics has a net margin of -148.11% compared to Aadi Bioscience's net margin of -270.04%. Aadi Bioscience's return on equity of -52.53% beat Nabriva Therapeutics' return on equity.
Aadi Bioscience has a consensus target price of $24.67, indicating a potential upside of 1,158.50%.
Nabriva Therapeutics has higher revenue and earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by insiders. Comparatively, 35.8% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Aadi Bioscience beats Nabriva Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Nabriva Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nabriva Therapeutics Competitors List
Related Companies and Tools
